HomeCompareEIGRQ vs MAIN

EIGRQ vs MAIN: Dividend Comparison 2026

EIGRQ yields 23.53% · MAIN yields 7.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MAIN wins by $47.86M in total portfolio value· pulled ahead in Year 3
10 years
EIGRQ
EIGRQ
● Live price
23.53%
Share price
$8.50
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$90.5K
Annual income
$9,663.72
Full EIGRQ calculator →
MAIN
Main Street Capital Corporation
● Live price
7.09%
Share price
$51.65
Annual div
$3.66
5Y div CAGR
72.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.95M
Annual income
$40,208,699.11
Full MAIN calculator →

Portfolio growth — EIGRQ vs MAIN

📍 MAIN pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEIGRQMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EIGRQ + MAIN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EIGRQ pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EIGRQ
Annual income on $10K today (after 15% tax)
$2,000.00/yr
After 10yr DRIP, annual income (after tax)
$8,214.16/yr
MAIN
Annual income on $10K today (after 15% tax)
$602.32/yr
After 10yr DRIP, annual income (after tax)
$34,177,394.24/yr
At 15% tax rate, MAIN beats the other by $34,169,180.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EIGRQ + MAIN for your $10,000?

EIGRQ: 50%MAIN: 50%
100% MAIN50/50100% EIGRQ
Portfolio after 10yr
$24.02M
Annual income
$20,109,181.42/yr
Blended yield
83.72%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MAIN right now

EIGRQ
No analyst data
Altman Z
-24.3
Piotroski
4/9
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+26.3% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EIGRQ buys
0
MAIN buys
0
No recent congressional trades found for EIGRQ or MAIN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEIGRQMAIN
Forward yield23.53%7.09%
Annual dividend / share$2.00$3.66
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%72.7%
Portfolio after 10y$90.5K$47.95M
Annual income after 10y$9,663.72$40,208,699.11
Total dividends collected$55.7K$46.82M
Payment frequencyquarterlymonthly
SectorStockBDC

Year-by-year: EIGRQ vs MAIN ($10,000, DRIP)

YearEIGRQ PortfolioEIGRQ Income/yrMAIN PortfolioMAIN Income/yrGap
1$13,053$2,352.94$12,464$1,223.78+$589.00EIGRQ
2$16,837$2,870.36$16,353$2,343.58+$484.00EIGRQ
3← crossover$21,476$3,460.26$23,105$4,724.42$1.6KMAIN
4$27,104$4,124.87$36,226$10,256.23$9.1KMAIN
5$33,867$4,865.30$65,426$24,707.64$31.6KMAIN
6$41,919$5,681.51$142,101$68,562.02$100.2KMAIN
7$51,425$6,572.30$388,521$228,799.95$337.1KMAIN
8$62,561$7,535.33$1,397,868$961,169.80$1.34MMAIN
9$75,507$8,567.24$6,884,663$5,313,459.69$6.81MMAIN
10$90,456$9,663.72$47,947,060$40,208,699.11$47.86MMAIN

EIGRQ vs MAIN: Complete Analysis 2026

EIGRQStock

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that is in phase II and III investigator studies of mild and moderate COVID-19; and Avexitide, which is in Phase II for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia. The company is headquartered in Palo Alto, California. On April 1, 2024, Eiger BioPharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.

Full EIGRQ Calculator →

MAINBDC

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies generally with annual revenues between $5 million and $300 million. It prefers to invest in ranging between $2 million and $75 million in equity investment and enterprise value in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $50 million per transaction in debt investment value and in the range of $1 million and $20 million in annual EBITDA. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minority and up to 50 percent majority equity investments. Main Street Capital Corporation was founded in 2007 and is based in Houston, Texas with an additional office in Chojnów, Poland.

Full MAIN Calculator →
📬

Get this EIGRQ vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EIGRQ vs SCHDEIGRQ vs JEPIEIGRQ vs OEIGRQ vs KOEIGRQ vs ARCCEIGRQ vs HTGCEIGRQ vs GBDCEIGRQ vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.